GlyTR Therapeutics is pioneering a new class of immunotherapeutic agents that operate independently of traditional antibody-based approaches. This innovative platform targets tumor-associated carbohydrate antigens that are commonly expressed across a wide range of cancers, including both solid tumors and hematological malignancies like leukemia. By focusing on these previously untapped targets, GlyTR aims to address the limitations of existing immunotherapies, which often struggle with specificity and effectiveness due to the limited number of cancer-specific protein antigens and the potential for off-target effects that can harm normal cells.

The technology developed by GlyTR Therapeutics includes the generation of bi-specific proteins and chimeric antigen receptor T cells (CAR T), enabling a more versatile and effective response against multiple cancer types. This approach allows a single GlyTR therapeutic to induce the destruction of various cancers, thereby revolutionizing cancer treatment. Founded by Dr. Michael Demetriou and Dr. Raymond Zhou, the company builds on extensive research from UC Irvine, positioning itself at the forefront of cancer care innovation.

United States

GlyTR Therapeutics Inc. was co-founded by Professor Michael Demetriou and Dr. Raymond Zhou in 2016 to accelerate the application of GlyTR immunotherapy to treat cancer in humans. GlyTR overcomes many of the shortcomings of current immunotherapies by binding to never-before targeted tumor-associated glycans expressed in virtually all types of cancer. GlyTR Therapeutics Inc. has been incubating at EvoNexus in Irvine and has received support by UCI’s Applied Innovation Center located at The Cove.

GlyTR Therapeutics

Company Details